Oncorus Inc. has closed a $79.5m series B round to initiate the first clinical trial for its herpes simplex-based oncolytic virus technology platform and select the first product candidate for its other platform using a synthetic virus for intravenous, systemic administration that enables repeat dosing in early 2020, the firm announced 21 August.
CEO Ted Ashburn told Scrip that the company believes it has two oncolytic virus platforms that overcome certain challenges for...